Fiche publication
Date publication
avril 2020
Journal
Cancers
Auteurs
Membres identifiés du Cancéropôle Est :
Dr AMARAL Teresa Maria
Tous les auteurs :
Amaral T, Schulze M, Sinnberg T, Nieser M, Martus P, Battke F, Garbe C, Biskup S, Forschner A
Lien Pubmed
Résumé
Combined immunotherapy has significantly improved survival of patients with advanced melanoma, but there are still patients that do not benefit from it. Early biomarkers that indicate potential resistance would be highly relevant for these patients.
Mots clés
advanced melanoma, immune checkpoint inhibitors, pathogenic/likely pathogenic germline variant, resistance to immunotherapy
Référence
Cancers (Basel). 2020 04 28;12(5):
